IL6 and esophageal squamous cell carcinoma: This implies that in spite of the high level of PD-L1 expression, IL-6 may also contribute to the low response rate to immunotherapy in ESCC patients by mediating CD8+ T depletion, which prevents PD-L1 blockers from fully exerting their effects.